Metolazone 2.5mg Tablet is an oral thiazide-like diuretic containing 2.5mg of metolazone. It is used medically to promote the elimination of excess sodium and water and is associated with treatment of oedema and hypertension. Metolazone 2.5mg tablets are documented in current U.S. prescription product labelling, while UK NHS guidance identifies 2.5mg as an imported/unlicensed metolazone presentation rather than the licensed Xaqua strength.
Metolazone belongs to the diuretic class and is particularly used in specialist management of fluid retention associated with conditions such as heart failure and renal disease. Product availability, formulation and regulatory status vary by country.
Metolazone is used to help manage oedema, or excess fluid accumulation, and hypertension.
Diuretic therapy can be used in fluid retention associated with cardiovascular or renal conditions. Metolazone may also be used in specialist diuretic regimens when additional fluid removal is clinically required.
U.S. prescribing information identifies metolazone for the treatment of oedema associated with congestive heart failure and renal disease and for hypertension.
The current UK Xaqua indication includes oedema associated with kidney disease, oedema associated with congestive heart failure and mild to moderate hypertension.
Metolazone reduces the reabsorption of sodium and chloride in the renal tubules. This increases the amount of sodium and water eliminated in the urine, producing a diuretic effect.
Its thiazide-like action can remain clinically useful in patients with reduced renal function, which is one reason metolazone is used in specialist fluid-management strategies.
Metolazone may be used to reduce excess fluid associated with conditions including heart failure and kidney disease.
Because diuretic treatment can alter fluid volume and electrolyte concentrations, treatment requires appropriate medical monitoring, particularly in patients receiving multiple diuretics or who have impaired renal function.
Metolazone has antihypertensive activity in addition to its diuretic effect. Current product information identifies hypertension as a therapeutic indication.
Blood pressure response and renal/electrolyte status may need to be monitored during treatment.
Metolazone is used clinically in patients with fluid retention associated with renal disease. However, reduced kidney function can also increase the complexity of fluid and electrolyte management.
The UK product information highlights the need for monitoring renal function and electrolytes and advises caution in patients with significant renal impairment.
Metolazone is used in the management of oedema associated with congestive heart failure.
It may be used as part of specialist diuretic therapy, including in patients whose fluid retention is difficult to control with other diuretic treatment. Because combined diuretic treatment can substantially increase fluid and electrolyte losses, medical supervision is important.
Metolazone is manufactured in several strengths, including 2.5mg and 5mg.
The strength is not the only factor that determines the clinical effect of a metolazone product. Different metolazone formulations can have different bioavailability, and the UK MHRA has specifically warned about switching between Xaqua and other metolazone preparations.
For that reason, different metolazone products should not be treated as automatically interchangeable simply because they contain the same nominal milligram strength.
This is an important UK distinction.
Metolazone 2.5mg is the active-ingredient strength of the product described on this page.
Xaqua 5mg is a specific UK-licensed metolazone product manufactured by Renascience Pharma Ltd. Current UK NHS guidance states that Xaqua is available as 5mg tablets and that imported metolazone products have historically included 2.5mg presentations.
Therefore, an unspecified Metolazone 2.5mg Tablet should not automatically be marketed as “generic Xaqua 2.5mg”, because Xaqua is not licensed in the UK at 2.5mg.
Zaroxolyn® is a brand associated with metolazone and has a documented 2.5mg presentation. Current U.S. prescribing information identifies Zaroxolyn as metolazone and describes 2.5mg and 5mg tablets.
However, different metolazone formulations may have different bioavailability. U.S. product labelling explicitly warns that formulations equivalent to Zaroxolyn and formulations equivalent to Mykrox should not be interchanged because they are not therapeutically equivalent at the same doses.
Metolazone can cause clinically significant changes in fluid balance and electrolytes.
Potential adverse effects include:
The UK Xaqua SmPC highlights electrolyte abnormalities, hypotension, renal effects and other adverse reactions associated with metolazone treatment.
Patients with significant kidney disease, liver disease or pre-existing electrolyte disturbances require particular clinical attention.
Metolazone can interact with medicines that affect renal function, blood pressure or electrolyte balance.
Clinically relevant interaction categories include:
A healthcare professional should review the complete medication list before treatment.
Because metolazone affects fluid and electrolyte balance, monitoring may include:
The need and frequency of monitoring depend on the patient’s condition, kidney function and concurrent medicines.
Storage requirements depend on the specific manufacturer and product.
For example, current U.S. metolazone 2.5mg tablet labelling specifies controlled room-temperature storage and protection from light.
Always follow the storage instructions printed on the actual product packaging.
The UK regulatory position is important for this strength.
Current UK eMC information lists Xaqua 5mg Tablets as the licensed metolazone product, while NHS prescribing guidance states that imported metolazone presentations include 2.5mg tablets.
This means a Metolazone 2.5mg product should not automatically be described as a UK-licensed medicine. The specific manufacturer, country of origin and regulatory status should be checked before supply.
Metolazone 2.5mg tablets are established in international prescription markets. Current U.S. product information lists Metolazone Tablets USP 2.5mg, including commercial and institutional presentations.
Other markets may use different brands and formulations, including products marketed under metolazone or brand-specific names. Regulatory approval, reimbursement, prescription requirements and product availability should be verified for each country.
What is Metolazone 2.5mg Tablet?
Metolazone 2.5mg Tablet is an oral prescription diuretic containing 2.5mg of metolazone.
What is Metolazone 2.5mg used for?
Metolazone is used for oedema associated with conditions such as heart failure or kidney disease and for hypertension.
Is Metolazone a water tablet?
Yes. Metolazone is a diuretic that increases urinary sodium and water excretion.
Is Metolazone 2.5mg available in the UK?
2.5mg metolazone has been supplied in the UK as an imported/unlicensed presentation. The current licensed Xaqua product is 5mg.
Is Metolazone 2.5mg the same as Xaqua?
No. Xaqua is a specific 5mg UK-licensed metolazone product. A 2.5mg metolazone product should not automatically be described as Xaqua or as a generic equivalent of Xaqua.
Is Metolazone 2.5mg the same as Zaroxolyn 2.5mg?
Both contain metolazone, but formulation bioavailability can differ. Product labelling warns against assuming interchangeability between different metolazone formulations.
What are common Metolazone 2.5mg side effects?
Potential effects include electrolyte abnormalities, dizziness, headache, fatigue, hypotension, gastrointestinal symptoms and muscle cramps.
Can Metolazone affect potassium?
Yes. Metolazone can cause hypokalaemia and other electrolyte disturbances, so appropriate monitoring may be required.
Can Metolazone be used with other diuretics?
Combined diuretic treatment is used in some clinical situations, but it can substantially increase fluid and electrolyte losses and should be managed by a healthcare professional.
Is Metolazone 2.5mg prescription-only?
Metolazone is a prescription medicine in the markets cited here. Exact legal classification and dispensing requirements depend on the country and product.
Is Metolazone 2.5mg available internationally?
Yes, metolazone 2.5mg tablets are documented in international prescription markets, but specific brands and regulatory status vary by country.
Last Updated: September 19, 2026 | Medically Reviewed By: Licensed Pharmacist
Medical Disclaimer: This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Metolazone can significantly affect fluid balance, electrolytes, blood pressure and renal function. Always consult a qualified healthcare professional before starting, stopping or changing prescription treatment.
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.